Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATIC | P31939 | 1/20 | 0.41 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.41 |
| ▸ | ACLY | P53396 | 5/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.38 |
| ▸ | MOGAT2 | Q3SYC2 | 1/20 | 0.37 |
| ▸ | APP | P05067 | 1/20 | 0.35 |
| ▸ | GPR27 | Q9NS67 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31085700 | 1.00 | ATIC (0.41) | ATICCRBNACLYHSD11B1MOGAT2 | |
| SCHEMBL24696659 | 0.93 | CRBN (0.47) | ATICCRBNACLYHSD11B1MOGAT2 | |
| SCHEMBL31085788 | 0.93 | CRBN (0.47) | ATICCRBNACLYHSD11B1MOGAT2 | |
| SCHEMBL31086076 | 0.92 | ATIC (0.41) | ATICCRBNACLYHSD11B1MOGAT2 | |
| SCHEMBL24697648 | 0.92 | ATIC (0.41) | ATICCRBNACLYHSD11B1MOGAT2 | |
| SCHEMBL31086045 | 0.91 | ATIC (0.40) | ATICCRBNACLYMOGAT2APP | |
| SCHEMBL31085832 | 0.91 | CRBN (0.42) | ATICCRBNACLYHSD11B1MOGAT2 | |
| SCHEMBL31085907 | 0.89 | ATIC (0.43) | ATICCRBNACLYMOGAT2CYP3A4 | |
| SCHEMBL31086121 | 0.89 | ATIC (0.42) | ATICCRBNACLYMOGAT2APP | |
| SCHEMBL31085862 | 0.88 | ACLY (0.44) | ATICCRBNACLYGPR27 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022254027-A1 | 3-PYRROLYLSULFONAMIDE COMPOUNDS AS GPR17 ANTAGONISTS | REWIND THERAPEUTICS NV (BE) | 2022-12-08 | — | — | WO | disclosed |